|
GB1528382A
(en)
*
|
1974-12-26 |
1978-10-11 |
Teijin Ltd |
Cyclopentene diols and acyl esters thereof and processes for their preparation
|
|
US4738954A
(en)
*
|
1985-11-06 |
1988-04-19 |
Warner-Lambert Company |
Novel N6 -substituted-5'-oxidized adenosine analogs
|
|
US4954504A
(en)
*
|
1986-11-14 |
1990-09-04 |
Ciba-Geigy Corporation |
N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
|
|
US5688774A
(en)
*
|
1993-07-13 |
1997-11-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
A3 adenosine receptor agonists
|
|
JP2000502709A
(ja)
*
|
1996-01-02 |
2000-03-07 |
ローヌ―プーラン ローラー ファーマシューティカルズ インコーポレイテッド |
2,4―ジヒドロキシピリジン及び2,4―ジヒドロキシ―3―ニトロピリジンの製造方法
|
|
US6376472B1
(en)
*
|
1996-07-08 |
2002-04-23 |
Aventis Pharmaceuticals, Inc. |
Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
|
|
GB9813554D0
(en)
*
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
|
CN1383427A
(zh)
*
|
1998-12-31 |
2002-12-04 |
阿温蒂斯药物公司 |
制备n6-取代的脱氮杂一腺苷衍生物的方法
|
|
US7427606B2
(en)
*
|
1999-02-01 |
2008-09-23 |
University Of Virginia Patent Foundation |
Method to reduce inflammatory response in transplanted tissue
|
|
US6403567B1
(en)
*
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
|
US6586413B2
(en)
*
|
1999-11-05 |
2003-07-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
|
|
CA2434906C
(en)
*
|
2001-01-16 |
2008-08-19 |
Can-Fite Biopharma Ltd. |
Use of an adenosine a3 receptor agonist for inhibition of viral replication
|
|
US20040162422A1
(en)
*
|
2001-03-20 |
2004-08-19 |
Adrian Hall |
Chemical compounds
|
|
EP1258247A1
(en)
*
|
2001-05-14 |
2002-11-20 |
Aventis Pharma Deutschland GmbH |
Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
|
|
US7414036B2
(en)
*
|
2002-01-25 |
2008-08-19 |
Muscagen Limited |
Compounds useful as A3 adenosine receptor agonists
|
|
EP1699459B1
(en)
*
|
2003-12-29 |
2007-06-06 |
Can-Fite Biopharma Ltd. |
Method for treatment of multiple sclerosis
|
|
ES2432113T3
(es)
*
|
2004-07-28 |
2013-11-29 |
Can-Fite Biopharma Ltd. |
Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
|
|
US7825102B2
(en)
*
|
2004-07-28 |
2010-11-02 |
Can-Fite Biopharma Ltd. |
Treatment of dry eye conditions
|
|
KR20070050484A
(ko)
*
|
2004-09-09 |
2007-05-15 |
더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
A1 및 a3 아데노신 수용체 아고니스트로서의 퓨린 유도체
|
|
GT200500281A
(es)
*
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
US7176172B2
(en)
*
|
2004-10-25 |
2007-02-13 |
Unilever Home & Personal Care Usa, Division Of Conopco, Inc. |
Quaternary ammonium polyol salts as anti-aging actives in personal care compositions
|
|
US20080051364A1
(en)
*
|
2004-11-08 |
2008-02-28 |
Pninna Fishman |
Therapeutic Treatment of Accelerated Bone Resorption
|
|
GB0500785D0
(en)
*
|
2005-01-14 |
2005-02-23 |
Novartis Ag |
Organic compounds
|
|
WO2006084281A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of e1 activating enzymes
|
|
JP5339916B2
(ja)
*
|
2005-11-30 |
2013-11-13 |
キャン−ファイト・バイオファーマ・リミテッド |
骨関節炎の治療におけるa3アデノシン受容体アゴニストの使用
|
|
DK1983990T3
(da)
*
|
2006-01-26 |
2011-07-11 |
Us Gov Health & Human Serv |
Allosteriske A3-adenosin-receptormodulatorer
|
|
HRP20120786T1
(hr)
*
|
2006-02-02 |
2012-11-30 |
Millennium Pharmaceuticals, Inc. |
Inhibitori aktivirajuä†eg enzima e1
|
|
GB0607950D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607954D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
HRP20120494T1
(hr)
*
|
2006-04-21 |
2012-08-31 |
Novartis Ag |
Derivati purina za uporabu kao agonista adenozin a2a receptora
|
|
GB0607945D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607948D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607951D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
EP1889846A1
(en)
*
|
2006-07-13 |
2008-02-20 |
Novartis AG |
Purine derivatives as A2a agonists
|
|
US8008307B2
(en)
*
|
2006-08-08 |
2011-08-30 |
Millennium Pharmaceuticals, Inc. |
Heteroaryl compounds useful as inhibitors of E1 activating enzymes
|
|
EP1903044A1
(en)
*
|
2006-09-14 |
2008-03-26 |
Novartis AG |
Adenosine Derivatives as A2A Receptor Agonists
|
|
JP2010508835A
(ja)
*
|
2006-11-10 |
2010-03-25 |
ノバルティス アーゲー |
シクロペンテンジオールモノアセテート誘導体
|
|
US20090181934A1
(en)
*
|
2007-10-17 |
2009-07-16 |
Novartis Ag |
Organic Compounds
|
|
KR20100068286A
(ko)
*
|
2007-10-17 |
2010-06-22 |
노파르티스 아게 |
아데노신 a1 수용체 리간드로서의 퓨린 유도체
|